SkylineDX’s predictive melanoma test secures FDA breakthrough designation
July 1, 2026
SkylineDX’s test stratifies cutaneous melanoma patients into metastatic risk categories to inform treatment decisions.
SkylineDX’s test stratifies cutaneous melanoma patients into metastatic risk categories to inform treatment decisions.